Cargando…

Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved

BACKGROUND: Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. CASE PRESENTATION: We discuss t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saita, Chiaki, Goto, Risa, Aruga, Tomoyuki, Idera, Nami, Honda, Yayoi, Horiguchi, Kazumi, Miyamoto, Hiromi, Horiguchi, Shinichiro, Yamashita, Toshinari, Kuroi, Katsumasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727271/
https://www.ncbi.nlm.nih.gov/pubmed/26813772
http://dx.doi.org/10.1186/s13104-016-1854-4
_version_ 1782411935493390336
author Saita, Chiaki
Goto, Risa
Aruga, Tomoyuki
Idera, Nami
Honda, Yayoi
Horiguchi, Kazumi
Miyamoto, Hiromi
Horiguchi, Shinichiro
Yamashita, Toshinari
Kuroi, Katsumasa
author_facet Saita, Chiaki
Goto, Risa
Aruga, Tomoyuki
Idera, Nami
Honda, Yayoi
Horiguchi, Kazumi
Miyamoto, Hiromi
Horiguchi, Shinichiro
Yamashita, Toshinari
Kuroi, Katsumasa
author_sort Saita, Chiaki
collection PubMed
description BACKGROUND: Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. CASE PRESENTATION: We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. CONCLUSION: Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.
format Online
Article
Text
id pubmed-4727271
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47272712016-01-27 Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved Saita, Chiaki Goto, Risa Aruga, Tomoyuki Idera, Nami Honda, Yayoi Horiguchi, Kazumi Miyamoto, Hiromi Horiguchi, Shinichiro Yamashita, Toshinari Kuroi, Katsumasa BMC Res Notes Case Report BACKGROUND: Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. CASE PRESENTATION: We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. CONCLUSION: Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy. BioMed Central 2016-01-26 /pmc/articles/PMC4727271/ /pubmed/26813772 http://dx.doi.org/10.1186/s13104-016-1854-4 Text en © Saita et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Saita, Chiaki
Goto, Risa
Aruga, Tomoyuki
Idera, Nami
Honda, Yayoi
Horiguchi, Kazumi
Miyamoto, Hiromi
Horiguchi, Shinichiro
Yamashita, Toshinari
Kuroi, Katsumasa
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
title Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
title_full Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
title_fullStr Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
title_full_unstemmed Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
title_short Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
title_sort invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727271/
https://www.ncbi.nlm.nih.gov/pubmed/26813772
http://dx.doi.org/10.1186/s13104-016-1854-4
work_keys_str_mv AT saitachiaki invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT gotorisa invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT arugatomoyuki invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT ideranami invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT hondayayoi invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT horiguchikazumi invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT miyamotohiromi invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT horiguchishinichiro invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT yamashitatoshinari invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved
AT kuroikatsumasa invasivepapillarycarcinomatreatedwithneoadjuvantendocrinetherapyinwhichpathologicalcompleteresponsewasachieved